Evidence map›Paper›PMID 41550662›Full record

ArticlePharmaceutical science advances2025

Artificial neural network guided optimization of tenofovir and Cyanovirin-N multipurpose preventive hydrogel formulation developed using the Box Behnken design model.

Karamot O Oyediran, Ibilola M Cardoso-Daodu, Peace Ofonabasi Bassey, Deborah A Ogundemuren, Ridwan Muhammed, Olusola E Ojo, Andrew N Amenaghawon, Chukwuemeka P Azubuike, Rachna Agarwal, Kondoru Haritha and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Karamot O OyediranDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, PMB 12003, Lagos, Nigeria.
Ibilola M Cardoso-DaoduDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, PMB 12003, Lagos, Nigeria.
Peace Ofonabasi BasseyDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, PMB 12003, Lagos, Nigeria.
Deborah A OgundemurenDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, PMB 12003, Lagos, Nigeria.
Ridwan MuhammedDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, PMB 12003, Lagos, Nigeria.
Olusola E OjoDepartment of Metallurgical and Materials Engineering, Faculty of Engineering, University of Lagos, Lagos, Nigeria.
Andrew N AmenaghawonDepartment of Chemical Engineering, Faculty of Engineering, University of Benin, Benin City, Nigeria.
Chukwuemeka P AzubuikeDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, PMB 12003, Lagos, Nigeria.
Rachna AgarwalBhabha Atomic Research Centre Mumbai, 400085, India.
Kondoru HarithaBhabha Atomic Research Centre Mumbai, 400085, India.
Margaret O IlomunayaDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, PMB 12003, Lagos, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tenofovir (TNF) is an antiretroviral drug that has being used as a topical microbicide to prevent human immunodeficiency virus transmission (HIV). Cyanovirin-N (CV-N) is a lectin protein that can bind to the HIV envelope glycoprotein and inhibit viral entry. The combination of TNF and CV-N may have synergistic effects and enhance the efficacy of microbicide. The aim of this study was to develop and optimize composite hydrogel formulations containing 1%TNF and 0.0005% CV-N using Box Behnken Design. A three-factor, three-level Box-Behnken design was employed to investigate the effects of the concentrations of PEG

Indexed as

Artificial neural networkBox Behnken designCyanovirin-NFluxHydrogelsTenofovir

Identifiers

PMID41550662
PMCPMC12709933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.